参考文献/References:
[1] 刘明波,何新叶,杨晓红,等.《中国心血管健康与疾病报告2023》要点解读[J]. 中国全科医学,2024,29(04):1-19.
[2] Pizzolo F,Castagna A,Olivieri O,et al. Basophil blood cell count is associated with enhanced factor Ⅱ plasma coagulant activity and increased risk of mortality in patients with stable coronary artery disease:not only neutrophils as prognostic marker in ischemic heart disease[J]. J Am Heart Assoc,2021,10(5):e018243.
[3] Fucà G,Guarini V,Antoniotti C,et al. The pan-immune-inflammation value is a new prognostic biomarker in metastatic colorectal cancer:results from a pooled-analysis of the Valentino and TRIBE first-line trials[J]. Br J Cancer,2020,123(3):403-409.
[4] Qi X,Qiao B,Song T,et al. Clinical utility of the pan-immune-inflammation value in breast cancer patients[J]. Front Oncol,2023,13:1223786.
[5] Baptista EA,Queiroz BL. Spatial analysis of cardiovascular mortality and associated factors around the world[J]. BMC Public Health,2022,22(1):1556.
[6] Maleki M,Tajlil A,Separham A,et al. Association of neutrophil to lymphocyte ratio(NLR) with angiographic SYNTAX score in patients with non-ST-Segment elevation acute coronary syndrome(NSTE-ACS)[J]. J Cardiovasc Thorac Res,2021,13(3):216-221.
[7] Li H,Meng S,Chen W,et al. Comparison of different systemic inflammatory markers in predicting clinical outcomes with syntax score in patients with non-ST segment elevation myocardial infarction:a retrospective study[J]. Int J Gen Med,2023,16:2595-2607.
[8] Cetinkaya Z ,Kelesoglu S,Tuncay A,et al. The role of pan-immune-inflammation value in determining the severity of coronary artery disease in NSTEMI patients [J]. J Clin Med,2024,13(5):1295.
[9] Peng A,Zhang B,Wang S,et al. Comparison of the value of various complex indexes of blood cell types and lipid levels in coronary heart disease[J]. Front Cardiovasc Med,2023,10:1284491.
[10] Demirtola A?,Erd?l MA,Mammadli A,et al. Predicting coronary artery severity in patients undergoing coronary computed tomographic angiography:insights from pan-immune inflammation value and atherogenic index of plasma[J]. Nutr Metab Cardiovasc Dis,2024,34(10):2289-2297.
[11] Le A,Peng H,Golinsky D,et al. What causes premature coronary artery disease?[J] Curr Atheroscler Rep,2024,26(6):189-203.
[12] 徐敏敏. 泛免疫炎症值与早发冠心病及其冠脉病变严重程度的相关性分析[D]. 大连医科大学,2023,000437.
[13] Sagris M,Antonopoulos AS,Theofilis P,et al. Risk factors profile of young and older patients with myocardial infarction[J]. Cardiovasc Res,2022,118(10):2281-2292.
[14] 马春亚,林杰,丁仁. 泛免疫炎症指数与急性ST段抬高型心肌梗死患者介入术后不良预后的关系[J]. 心肺血管病杂志,2024,43(03):228-232.
[15] Liu Y,Liu J,Liu L,et al. Association of systemic inflammatory response index and pan-immune-inflammation-value with long-term adverse cardiovascular events in ST-segment elevation myocardial infarction patients after primary percutaneous coronary intervention [J]. J Inflamm Res,2023,16:3437-3454.
[16] Yang L,Guo J,Chen M,et al. Pan-immune-inflammatory value is superior to other inflammatory indicators in predicting inpatient major adverse cardiovascular events and severe coronary artery stenosis after percutaneous coronary intervention in STEMI patients[J]. Rev Cardiovasc Med,2024,25(8):294.
[17] Murat B,Murat S,Ozgeyik M,et al. Comparison of pan‐immune‐inflammation value with other inflammation markers of long‐term survival after ST-segment elevation myocardial infarction[J]. Eur J Clin Invest,2023,53(1):e13872.
[18] Jiang H,Li D,Xu T,et al. Systemic immune-inflammation index predicts contrast-induced acute kidney injury in patients undergoing coronary angiography:a cross-sectional study[J]. Front Med (Lausanne),2022,9:841601.
[19] Chillo P,Malaja NW,Kisenge P. Magnitude and associated factors of contrast induced nephropathy among patients undergoing coronary angiography and interventions at a cardiac referral hospital in Tanzania-a cross-sectional study[J]. Pan Afr Med J,2021,38:311.
[20] Akkaya S ,Cakmak U. Association between pan-immune-inflammation value and contrast-induced nephropathy with coronary angiography[J]. Medicina ( Kaunas),2024,60(6):1012.
[21] Cetinkaya Z,Kelesoglu S. The role of pan-immune-inflammation value in predicting contrast-induced nephropathy development in patients undergoing percutaneous coronary intervention due to NSTEMI[J]. Angiology,2023:33197231211107. DOI:10.1177/00033197231211107.
[22] Kurtul A,Gok M. Preinterventional pan-immune-inflammation value as a tool to predict postcontrast acute kidney injury among acute coronary syndrome patients implanted drug-eluting stents:a retrospective observational study[J]. Scand J Clin Lab Invest,2024,84(2):97-103.
[23] ?en F,Kurtul A,Bekler ?. Pan-immune-inflammation value is independently correlated to impaired coronary flow after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction[J]. Am J Cardiol,2024,211:153-159.
[24] Kaplangoray M,Toprak K,Deveci E,et al. Could pan-immune-inflammation value be a marker for the diagnosis of coronary slow flow phenomenon ?[J]. Cardiovasc Toxicol,2024,24(5):519-526.
[25] Bayramo?lu A,Hidayet ?. Association between pan-immune-inflammation value and no-reflow in patients with ST elevation myocardial infarction undergoing percutaneous coronary intervention[J]. Scand J Clin Lab Invest,2023,83(6):384-389.
[26] Kelesoglu S,Yilmaz Y,Elc?k D,et al. Systemic immune inflammation index:a novel predictor for coronary collateral circulation[J]. Perfusion,2022,37(6):605-612.
[27] Yilmaz Y,Kelesoglu S. The importance of pan-immune inflammation value(PIV) in predicting coronary collateral circulation in stable coronary artery patients[J]. Angiology,2024:33197241258529. DOI:10.1177/00033197241258529.
[28] Zhang B,Li Y,Peng A,et al. Association between the pan-immune-inflammation value and coronary collateral circulation in chronic total coronary occlusive patients[J]. BMC Cardiovasc Disord,2024,24(1):458.
[29] Onnis C,Virmani R,Kawai K,et al. Coronary artery calcification:current concepts and clinical implications[J]. Circulation,2024,149(3):251-266.
[30] Jin C,Li X,Luo Y,et al. Associations between pan-immune-inflammation value and abdominal aortic calcification:a cross-sectional study[J]. Front Immunol,2024,15:1370516.
[31] Adamo L,Rocha-Resende C,Prabhu SD,et al. Reappraising the role of inflammation in heart failure[J]. Nat Rev Cardiol,2020,17(5):269-285.
[32] Inan D,Erdogan A,Pay L,et al. The prognostic impact of inflammation in patients with decompensated acute heart failure,as assessed using the pan-immune inflammation value (PIV)[J]. Scand J Clin Lab Invest,2023,83(6):371-378.
[33] Murat B,Murat S,Alt?nbas ME,et al. Association of pan immune-inflammation value with long term outcomes of acute decompensated heart failure[J]. Arq Bras Cardiol,2024,121(6):e20230817.
[34] Madhur MS,Elijovich F,Alexander MR,et al. Hypertension:do inflammation and immunity hold the key to solving this epidemic?[J]. Circ Res,2021,128(7):908-933.
[35] Chen J,Luo C,Tan D,et al. J-shaped associations of pan-immune-inflammation value and systemic inflammation response index with stroke among American adults with hypertension:evidence from NHANES 1999–2020[J]. Front Neurol,2024,15:1417863.
[36] Sivri F,Güng?r H,?okp?nar S,et al. Value of preoperative platelet-to-lymphocyte and neutrophil-to-lymphocyte ratios in predicting postoperative atrial fibrillation in patients undergoing lung resection[J]. J Tehran Heart Cent,2022,17(4):236-242.
[37] Eyiol A. The relationship of pan-immune-inflammation value(PIV) and HALP score with prognosis in patients with atrial fibrillation[J]. Medicine(Baltimore),2024,103(36):e39643.
[38] Gao S ,Zhang K,Zhou C,et al. HSPB6 deficiency promotes the development of aortic dissection and rupture[J]. Lab Invest,2024,104(3):100326.
[39] Yu X,Chen Y,Peng Y,et al. The pan-immune inflammation value at admission predicts postoperative in-hospital mortality in patients with acute type A aortic dissection[J]. J Inflamm Res,2024,17:5223-5234.
相似文献/References:
[1]白春兰,张军.正五聚蛋白-3:新型心血管病炎性标志物[J].心血管病学进展,2016,(1):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
BAI Chunlan,ZHANG Jun.Pentraxin-3: A Novel Inflammation Biomarker for Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(4):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
[2]任茂佳,贺文帅,张琪,等.围绝经期对心血管疾病相关危险因素的影响[J].心血管病学进展,2019,(6):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
REN Maojia,HE Wenshuai,ZHANG Qi,et al.Effects of Perimenopause on Cardiovascular Risk Factors[J].Advances in Cardiovascular Diseases,2019,(4):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
[3]尹琳 黄从新.JP2蛋白和心血管疾病的研究进展[J].心血管病学进展,2019,(7):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
YIN Lin HUANG Congxin.Research Progress of JP2 Protein and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(4):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
[4]朱峰 汪汉 蔡琳.抗体与心血管疾病[J].心血管病学进展,2019,(7):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
ZHU FengWANG HanCAI Lin.Antibodies and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(4):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
[5]邱明仙 王正龙 许官学.心肌肌球蛋白结合蛋白-C磷酸化与心血管疾病关系的研究进展[J].心血管病学进展,2019,(7):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
QIU MingxianWANG ZhenglongXU Guanxue.Research Progress of the Relationship Between Cardiac Myosin Binding Protein-C and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(4):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
[6]姬楠楠 杨晓静 谢勇.单核细胞/高密度脂蛋白比值与心血管疾病的研究进展[J].心血管病学进展,2019,(7):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
JI Nannan YANG Xiaojing XIE Yong.Monocyte/High-density Lipoprotein Ratio and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(4):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
[7]渠海贤 李涛 程流泉.人工智能在心脏磁共振成像中的应用进展[J].心血管病学进展,2019,(5):659.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.001]
[8]侯冬华 郝丽荣.长正五聚蛋白3在动脉粥样硬化和心血管疾病中作用研究的新进展[J].心血管病学进展,2019,(5):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
HOU Donghua H AO Lirong.The Study of Atherosclerosis and Cardiovascular Diseases with Pentapycin 3[J].Advances in Cardiovascular Diseases,2019,(4):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
[9]张维 张恒 康品方.外泌体在心血管疾病中的研究进展[J].心血管病学进展,2019,(5):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
Zhang WeiKang Pinfang.Exosome in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(4):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
[10]韦莹 刘书旺 李蕾 崔鸣.生长分化因子-15在心房颤动中的研究进展[J].心血管病学进展,2019,(8):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]
WEI Ying,LIU Shuwang,LI Lei,et al.Growth Differentiation Factor-15 in Development of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2019,(4):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]